| Recruiting | BAY3401016; Biomarker Study Alport NCT07211685 | Bayer | Phase 2 |
| Not Yet Recruiting | Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome NCT06731192 | Guangzhou Women and Children's Medical Center | Phase 2 / Phase 3 |
| Completed | Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) NCT06425055 | Enyo Pharma | Phase 2 |
| Active Not Recruiting | Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alpo NCT06499948 | Stefan Lujinschi | Phase 4 |
| Completed | A Study to Evaluate Setanaxib in Patients With Alport Syndrome NCT06274489 | Calliditas Therapeutics AB | Phase 1 / Phase 2 |
| Active Not Recruiting | Effects of Dapagliflozin on Progression of Alport Syndrome NCT06226896 | Nanjing University School of Medicine | — |
| Recruiting | ASF Alport Patient Registry NCT06526741 | Alport Syndrome Foundation | — |
| Unknown | Treatment With Metformin in Chinese Children With Alport Syndrome NCT05655728 | Peking University First Hospital | Phase 4 |
| Completed | A Study of ELX-02 in Patients With Alport Syndrome NCT05448755 | Eloxx Pharmaceuticals, Inc. | Phase 2 |
| Completed | Baby Detect : Genomic Newborn Screening NCT05687474 | Centre Hospitalier Universitaire de Liege | — |
| Completed | Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis NCT05267262 | River 3 Renal Corp. | Phase 2 |
| Recruiting | NEPTUNE Match Study NCT04571658 | University of Michigan | N/A |
| Not Yet Recruiting | Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants NCT05133050 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Recruiting | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases NCT05003986 | Travere Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Atrasentan in Patients With Proteinuric Glomerular Diseases NCT04573920 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Genotype-Phenotype Correlations in Patients With Alport Syndrome NCT04947813 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Terminated | Study of Lademirsen (SAR339375) in Patients With Alport Syndrome NCT02855268 | Genzyme, a Sanofi Company | Phase 2 |
| Terminated | An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) NCT03749447 | Biogen | Phase 3 |
| Completed | A Study of RG-012 in Subjects With Alport Syndrome NCT03373786 | Genzyme, a Sanofi Company | Phase 1 |
| Recruiting | Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport) NCT05927467 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL NCT03019185 | Biogen | Phase 2 / Phase 3 |
| Terminated | Human Urine Sample Collection for Alport Nephropathy Biomarker Studies NCT01602835 | Novartis Pharmaceuticals | — |
| Completed | Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study NCT01696253 | University of Minnesota | — |
| Completed | Urinary Biomarkers of the Progression of Alport Kidney Disease NCT01705132 | University of Minnesota | — |
| Recruiting | National Registry of Rare Kidney Diseases NCT06065852 | UK Kidney Association | — |
| Completed | Alport Syndrome Treatments and Outcomes Registry NCT00481130 | University of Minnesota | — |
| Completed | A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome NCT00622544 | University of Minnesota | — |
| Completed | Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome NCT00309257 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Recruiting | Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome NCT02378805 | University Hospital Goettingen | — |